Endra Life Sciences INC. 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share NDRA The Nasdaq Stock Mar
• $150 — shall pay Mr. Thornton at a rate of (i) $150 per hour for the first five hours per c
• $100 — t five hours per calendar week and (ii) $100 per hour for any hours in excess of fiv
• $8,650 — r for an initial discounted base fee of $8,650 per month and at a rate of $124.70 per
• $124.70 — ee of $8,650 per month and at a rate of $124.70 per hour for hours beyond 16 per week,
• $10,800 — subject to an increase to a base fee of $10,800 per month and a rate of $156.00 per hou
• $156.00 — fee of $10,800 per month and a rate of $156.00 per hour for hours beyond 16 per week e

Filing Documents

• ea0267731-8k_endra.htm (8-K) — 27KB
• ea026773101ex10-1_endra.htm (EX-10.1) — 59KB
• ea026773101ex10-2_endra.htm (EX-10.2) — 35KB
• 0001213900-25-116103.txt ( ) — 309KB
• ndra-20251128.xsd (EX-101.SCH) — 3KB
• ndra-20251128_lab.xml (EX-101.LAB) — 33KB
• ndra-20251128_pre.xml (EX-101.PRE) — 22KB
• ea0267731-8k_endra_htm.xml (XML) — 4KB

02 Departure of Directors or Certain Officers; Appointment

Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 28, 2025, ENDRA Life Sciences Inc. (the "Company") entered into a Consulting Agreement with Michael Thornton (the "Consulting Agreement"), in connection with which Mr. Thornton resigned as the Company's Chief Technology Officer effective on such date. Pursuant to the Consulting Agreement, Mr. Thornton will provide commercialization services and certain deliverables to the Company, as may be requested by the Company from time to time, and the Company shall pay Mr. Thornton at a rate of (i) $150 per hour for the first five hours per calendar week and (ii) $100 per hour for any hours in excess of five hours per calendar week. The Consulting Agreement provides that all of Mr. Thornton's outstanding Options and Restricted Stock Units (each term as defined in the Company's 2016 Omnibus Incentive Plan) shall remain outstanding and continue to vest in accordance with their terms for so long as Mr. Thornton is providing services under the Consulting Agreement. The Consulting Agreement has an indefinite term and may be cancelled by either party with 15 days' notice to the other party. Additionally, on November 28, 2025, the Company entered into an Advisory Services Agreement (the "Advisory Services Agreement") with Impact Solve, LLC, a Washington limited liability company dba Impact Solutions ("Impact Solutions"), which supersedes and replaces Impact Solutions' prior services agreement with the Company. The Advisory Services Agreement provides for services (the "Services") to be provided to the Company by Richard Jacroux, the Company's Chief Financial Officer, pursuant to work orders to be agreed upon by Mr. Jacroux and the Company from time to time. The Advisory Services Agreement provides that the Company shall reimburse Impact Solutions for reasonable travel and any additional expenses that the parties may agree to in writing

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Consulting Agreement, dated as of November 28, 2025 by and between ENDRA Life Sciences Inc. and Michael Thornton 10.2 Advisory Services Agreement, dated as of November 28, 2025 by and between ENDRA Life Sciences Inc. and Richard Jacroux 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENDRA Life Sciences Inc. November 28, 2025 By: /s/ Alexander Tokman Name: Alexander Tokman Title: Chief Executive Officer and Chairman 2

View Full Filing

View this 8-K filing on SEC EDGAR